Beta-thalassemia: cross-border specialty drug access for international patients

Quick orientation

Beta-thalassemia affects approximately 1 in 100,000 people globally, with substantially higher carrier and disease frequencies in the Mediterranean, Middle East, North Africa, and South and Southeast Asia. Carrier frequency in some Mediterranean and Middle Eastern populations exceeds 10 percent.

Typical age of onset. Severe transfusion-dependent forms typically present in the first 2 years of life; non-transfusion-dependent forms can present later.

Severity tiers. Severity ranges from minor (carrier, generally asymptomatic) to intermedia to major (transfusion-dependent thalassemia, TDT) which requires lifelong transfusion support and iron chelation.

Why specialty drugs for Beta-thalassemia are hard to access internationally

Two gene therapies (Zynteglo, Casgevy) and a targeted ineffective-erythropoiesis modulator (Reblozyl) are now FDA-approved for TDT. Gene therapies are particularly hard to access internationally given the requirement for specialized treatment centers, manufacturing logistics, and pre-conditioning chemotherapy. Reblozyl has broader global registration but is unevenly reimbursed in high-prevalence countries.

Treatments approved by the FDA

• Zynteglo (betibeglogene autotemcel) — FDA approval: 2022. Mechanism: Autologous ex vivo gene therapy adding a functional beta-globin gene. Route: One-time intravenous infusion of modified autologous cells. US WAC ballpark: Approximately USD 2.8 million one-time. Country pricing: UAE · Qatar · Jordan · Oman.
• Casgevy (exagamglogene autotemcel) — FDA approval: 2023 (TDT 2024). Mechanism: CRISPR/Cas9 gene-edited autologous cell therapy. Route: One-time intravenous infusion of modified autologous cells. US WAC ballpark: Approximately USD 2.2 million one-time. Country pricing: UAE · Saudi Arabia · India · Qatar · Kuwait · Egypt.
• Reblozyl (luspatercept) — FDA approval: 2019. Mechanism: Erythroid maturation agent that traps TGF-beta superfamily ligands. Route: Subcutaneous injection every 3 weeks. US WAC ballpark: Approximately USD 30,000 to 60,000 per cycle.

Cross-border pathways used for Beta-thalassemia

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Medical Tourism Access

What your physician needs to know

• Confirm transfusion-dependent versus non-transfusion-dependent status.
• For gene therapies, evaluate cardiac, hepatic, and endocrine function before pre-conditioning chemotherapy.
• Iron chelation status, ferritin trends, and end-organ damage inform timing.
• Gene therapies require treatment at qualified centers; medical-tourism pathways are often more relevant than supply-only pathways.
• Some destination countries restrict pediatric travel for one-time cell therapies; family planning is part of the protocol.

Common questions

Can I receive Casgevy or Zynteglo abroad?

Both are one-time autologous cell therapies that must be administered at qualified treatment centers, most of which are currently in the United States and Europe. Reserve Meds supports the medical-tourism pathway when patients travel to a qualified center.

Is Reblozyl appropriate for my case?

Reblozyl is FDA-approved for TDT in adults requiring regular RBC transfusions. Your hematologist confirms eligibility.

What about iron chelators?

Several iron chelators are widely registered globally and typically available locally. Our scope is on specialty drugs that are unregistered or not reimbursed.

Do gene therapies cure beta-thalassemia?

Both Zynteglo and Casgevy have shown transfusion independence in most treated patients in clinical trials. Long-term follow-up continues.

What is the timeline for a gene therapy program?

From referral to infusion typically takes 6 to 12 months including pre-conditioning, cell collection, manufacturing, and admission. Reserve Meds coordinates the supporting logistics.

Who pays for medical-tourism access?

Reserve Meds operates a cash-pay model. Some families combine personal funds with charitable foundation support. We do not bill insurance.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Beta-thalassemia, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Beta-thalassemia

Reserved for you.